The problem of cardiac safety of nonsteroidal anti-inflammatory drugs

被引：0
作者：
Shostak, N. A. [1 ]
Klimenko, A. A. [1 ]
Demidova, N. A. [1 ]
Kondrashov, A. A. [1 ]
机构：
[1] NI Pirogov Russian Natl Res Med Univ, Minist Hlth Russia, Moscow, Russia
来源：
TERAPEVTICHESKII ARKHIV | 2016年 / 88卷 / 05期
关键词：
nonsteroidal anti-inflammatory drugs; meloxicam; cardiovascular risk; safety; BLOOD-PRESSURE; CARDIOVASCULAR EVENTS; PLATELET-FUNCTION; INHIBITORS; RISK; ROFECOXIB; MELOXICAM; METAANALYSIS; CELECOXIB; NAPROXEN;
D O I：
10.17116/terarkh2016885113-117
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The paper considers an update on the mechanisms for the development of adverse reactions of nonsteroidal anti-inflammatory drugs on the cardiovascular system.
引用
收藏
页码：113 / 117
页数：7
相关论文
共 39 条
[1]   Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without ST-segment elevation - The nonsteroidal anti-inflammatory drugs in unstable angina treatment-2 (NUT-2) pilot study [J].
Altman, R ;
Luciardi, HL ;
Muntaner, J ;
Del Rio, F ;
Berman, SG ;
Lopez, R ;
Gonzalez, C .
CIRCULATION, 2002, 106 (02) :191-195
[2]  
Alvarez-Nemegyei J, 2006, REUMATOL CLIN, V2, P10, DOI 10.1016/S1699-258X(06)73014-5
[3]   The effect of COX-2-selective meloxicam on the myocardial, vascular and renal risks: a systematic review [J].
Asghar, Waheed ;
Jamali, Fakhreddin .
INFLAMMOPHARMACOLOGY, 2015, 23 (01) :1-16
[4]  
BELYAYEVA IB, 2008, FARMATIEKA, P19
[5]   Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. [J].
Bombardier, C ;
Laine, L ;
Reicin, A ;
Shapiro, D ;
Burgos-Vargas, R ;
Davis, B ;
Day, R ;
Ferraz, MB ;
Hawkey, CJ ;
Hochberg, MC ;
Kvien, TK ;
Schnitzer, TJ ;
Weaver, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (21) :1520-1528
[6]   Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial [J].
Bresalier, RS ;
Sandler, RS ;
Quan, H ;
Bolognese, JA ;
Oxenius, B ;
Horgan, K ;
Lines, C ;
Riddell, R ;
Morton, D ;
Lanas, A ;
Konstam, MA ;
Baron, JA .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (11) :1092-1102
[7]   Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis [J].
Caldwell, B ;
Aldington, S ;
Weatherall, M ;
Shirtcliffe, P ;
Beasley, R .
JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 2006, 99 (03) :132-140
[8]   Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects [J].
Capone, ML ;
Sciulli, MG ;
Tacconelli, S ;
Grana, M ;
Ricciotti, E ;
Renda, G ;
Di Gregorio, P ;
Merciaro, G ;
Patrignani, P .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 45 (08) :1295-1301
[9]   Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. [J].
Catella-Lawson, F ;
Reilly, MP ;
Kapoor, SC ;
Cucchiara, AJ ;
DeMarco, S ;
Tournier, B ;
Vyas, SN ;
FitzGerald, GA .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (25) :1809-1817
[10]   Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis [J].
Chan, Clara C. ;
Reid, Christopher M. ;
Aw, Tai-Juan ;
Liew, Danny ;
Haas, Steven Joseph ;
Krum, Henry .
JOURNAL OF HYPERTENSION, 2009, 27 (12) :2332-2341
1234